You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent inhibitor of cyclooxygenase (IC50 values are 0.1 and 0.4 μM for inhibition of human COX-1 and COX-2 respectively). Analgesic, anti-inflammatory and antipyretic in vivo. Inhibits tumor cell growth in vitro and in vivo. Regulates prostate stem cell antigen through activation of Akt kinase. Also inhibits fibroblast proliferation in vitro.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 244.26. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.09 mL||20.47 mL||40.94 mL|
|5 mM||0.82 mL||4.09 mL||8.19 mL|
|10 mM||0.41 mL||2.05 mL||4.09 mL|
|50 mM||0.08 mL||0.41 mL||0.82 mL|
References are publications that support the biological activity of the product.
Gierse et al (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem.J. 305 479 PMID: 7832763
Glenn et al (1973) The pharmacology of 2-(2-fluoro-4-biphenylyl)propionic acid (flurbiprofen). A potent non-steroidal anti-inflammatory drug. Agents Actions 3 210 PMID: 4776365
Hoferova et al (2002) The effect of nonsteroidal antiinflammatory drugs ibuprofen, flurbiprofen, and diclofenac on in vitro and in vivo growth of mouse fibrosarcoma. Cancer Invest. 20 490 PMID: 12094544
Zemskova et al (2006) Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem.Pharmacol. 72 1257 PMID: 16949054
If you know of a relevant reference for Flurbiprofen, please let us know.
View Related Products by Product Action
Keywords: Flurbiprofen, Flurbiprofen supplier, Cyclooxygenase, inhibitors, inhibits, COX, Oxidase, Oxygenases, Oxidases, stem, cells, Akt, kinases, Analgesics, anti-inflammatory, and, antipyretics, Stem, Cell, Signaling, 1769, Tocris Bioscience
Citations for Flurbiprofen
Citations are publications that use Tocris products.
Currently there are no citations for Flurbiprofen. Do you know of a great paper that uses Flurbiprofen from Tocris? Please let us know.
Reviews for Flurbiprofen
There are currently no reviews for this product. Be the first to review Flurbiprofen and earn rewards!
Have you used Flurbiprofen?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.